NCT00141349

Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369,003 in Adult Male Subject With Erectile Dysfunction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: Pfizer · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Conditions

• Impotence

Interventions

Type	Name	Description
DRUG	UK-369,003

Timeline

• Start date: 2005-02-01
• Completion: 2005-08-01
• First posted: 2005-09-01
• Last updated: 2006-07-25

Locations

39 sites across 1 country: United States